LV10192A - Farmaceitisks pretaptaukosanas sastavs - Google Patents

Farmaceitisks pretaptaukosanas sastavs

Info

Publication number
LV10192A
LV10192A LV930094A LV930094A LV10192A LV 10192 A LV10192 A LV 10192A LV 930094 A LV930094 A LV 930094A LV 930094 A LV930094 A LV 930094A LV 10192 A LV10192 A LV 10192A
Authority
LV
Latvia
Prior art keywords
obesity composition
pharmaceutical anti
ephedrine
human
reducing
Prior art date
Application number
LV930094A
Other languages
English (en)
Other versions
LV10192B (en
Inventor
Arne Astrup
Original Assignee
Nycomed Dak As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Dak As filed Critical Nycomed Dak As
Publication of LV10192A publication Critical patent/LV10192A/lv
Publication of LV10192B publication Critical patent/LV10192B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LVP-93-94A 1989-07-07 1993-02-03 A slimming pharmaceutical composition LV10192B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK339289A DK339289D0 (da) 1989-07-07 1989-07-07 Farmaceutisk praeparat
PCT/DK1990/000106 WO1991000730A1 (en) 1989-07-07 1990-04-20 A slimming pharmaceutical composition

Publications (2)

Publication Number Publication Date
LV10192A true LV10192A (lv) 1994-10-20
LV10192B LV10192B (en) 1995-06-20

Family

ID=8122369

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-93-94A LV10192B (en) 1989-07-07 1993-02-03 A slimming pharmaceutical composition

Country Status (19)

Country Link
US (1) US5422352A (lv)
EP (1) EP0480934B1 (lv)
JP (1) JP2584899B2 (lv)
KR (1) KR0159045B1 (lv)
AT (1) ATE107858T1 (lv)
AU (1) AU638992B2 (lv)
CA (1) CA2063598C (lv)
DE (1) DE69010336T2 (lv)
DK (2) DK339289D0 (lv)
ES (1) ES2055911T3 (lv)
FI (1) FI920026A0 (lv)
HK (1) HK1001821A1 (lv)
HU (1) HU220071B (lv)
LT (1) LT3536B (lv)
LV (1) LV10192B (lv)
NO (1) NO920051L (lv)
RU (1) RU2109511C1 (lv)
UA (1) UA27779C2 (lv)
WO (1) WO1991000730A1 (lv)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5865869A (en) * 1991-08-02 1999-02-02 Ecologel Usa, Inc. Solution for plant root watering
WO1994000432A1 (en) * 1992-06-30 1994-01-06 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Anorectic epinephrine derivatives
AU682156B2 (en) * 1992-10-15 1997-09-25 Dana-Farber Cancer Institute, Inc. Treatment of insulin resistance in obesity linked type II diabetes using antagonists to TNF-alpha function
ES2094687B1 (es) * 1994-08-02 1997-12-16 S A L V A T Lab Sa Combinacion farmaceutica contra la obesidad o el sobrepeso.
FR2746644A1 (fr) * 1996-03-18 1997-10-03 Firion Jackie Produit parapharmaceutique moderateur d'appetit
DE69638106D1 (de) * 1996-09-30 2010-02-11 Dennis Jones Regulation von Körpergewicht durch Materialien basierend auf Zitrusvariationen
US6224873B1 (en) 1996-09-30 2001-05-01 Zhishin, Llc Regulation of appetite, body weight and athletic function with materials derived from citrus varieties
CA2275663C (en) * 1996-12-23 2008-03-18 Robin Kenneth Stewart Phillips Pharmaceutical compositions comprising .alpha.-adrenergic agonists for the treatment of fecal incontinence
US5985282A (en) * 1997-01-22 1999-11-16 Hpf, L.L.C. Herbal appetite suppressant and weight loss composition
US6162455A (en) * 1997-01-22 2000-12-19 American Cyanamid Company Method for increasing lean meat, improving the lean meat to fat ratio and improving amino acid utilization in warm-blooded animals
US5798101A (en) * 1997-01-22 1998-08-25 Hpf, L.L.C. Herbal appetite suppressant and weight loss composition
HUP9700654A2 (hu) * 1997-03-26 1999-09-28 Dezső Korbonits Teobromin tartalmú köhögéscsillapító készítmények
US6468519B1 (en) * 1997-09-10 2002-10-22 Rutgers, The State University Of New Jersey Polyanhydrides with biologically active degradation products
US7232830B2 (en) 1998-06-26 2007-06-19 Elaine A Delack Method for treatment of neurodegenerative diseases and effects of aging
EP1094809A2 (en) * 1998-06-26 2001-05-02 Elaine A. Delack Use of histamine h2 mimicking substances for the treatment of multiple sclerosis
US6340482B1 (en) * 2000-05-18 2002-01-22 Zhishin, Llc Methods for inducing weight loss in a human with materials derived from Citrus varieties
US6113949A (en) * 1998-10-27 2000-09-05 Prolab Nutrition, Inc. Weight control product and method of treating hyperlipidemia and increasing vigor with said product
US6475514B1 (en) * 1998-12-03 2002-11-05 Andrew Blitzer Athletic patch
US6576272B1 (en) * 1999-03-05 2003-06-10 Twin Laboratories Incorporated Dietary supplement and method of using same
WO2001005356A2 (en) * 1999-07-20 2001-01-25 Natrol, Inc. Weight control product comprising a synergistic mixture of guggul extract, phosphate salt and metabolic stimulant
AU7066400A (en) * 1999-08-23 2001-03-19 The Administrators Of The Tulane Eductional Fund Modulation of the blood-brain barrier transporter for leptin
US6723737B1 (en) * 1999-10-20 2004-04-20 Eliezer Rapaport Methods, pharmaceutical and therapeutic compostions for administering adenosine
US8178150B2 (en) 2000-02-22 2012-05-15 Suzanne Jaffe Stillman Water containing soluble fiber
US7892586B2 (en) 2001-02-22 2011-02-22 Suzanne Jaffe Stillman Water containing soluble fiber
US7115297B2 (en) * 2000-02-22 2006-10-03 Suzanne Jaffe Stillman Nutritionally fortified liquid composition with added value delivery systems/elements/additives
DE10011541A1 (de) * 2000-03-06 2001-09-20 Reimann Hartmut Verwendung einer Kombination aus Ephedrin und Coffein und/oder Theophyllin zur Vitalisierung von Knochenfischen, Wasserzusatz zur Vitalisierung von Knochenfischen
US6316499B1 (en) 2000-05-18 2001-11-13 Zhishin, Llc Methods for increasing the muscle mass of a human with materials derived from citrus varieties
KR20030005204A (ko) * 2000-12-25 2003-01-17 가부시키가이샤 시세이도 교감신경 활성화 향료 조성물
US7048941B2 (en) * 2001-03-30 2006-05-23 New World Enterprizes, Inc. Chocolate composition as delivery system for nutrients and medications
WO2003022239A2 (en) * 2001-09-07 2003-03-20 Western Holdings Llc Stable water in oil aminophylline emulsions
GB0130763D0 (en) 2001-12-21 2002-02-06 Norgine Res Ltd Treatment methods
AU2003224507A1 (en) * 2002-04-19 2003-11-03 N.V. Nutricia Multiphasic diet
US8142810B2 (en) * 2002-05-30 2012-03-27 The Procter & Gamble Company Dietary method for modulating glucose metabolism and associated conditions and increasing longevity
US20040077530A1 (en) * 2002-10-18 2004-04-22 Robert Portman Composition for reducing caloric intake
US20040224031A1 (en) * 2003-05-06 2004-11-11 Antonio Zorzano Olarte Combination of amines and vanadium (IV)/(V) compounds for the treatment and/or prevention of diabetes mellitus
CA2559836C (en) 2003-10-17 2014-08-12 Diet Formulations Ltd. Thermogenic and fiber containing weight-loss supplement
US20050113456A1 (en) * 2003-11-20 2005-05-26 Aberg A.K. G. Method of decreasing fat deposits and body weight in mammals and birds
CA2455248A1 (en) * 2004-01-29 2005-07-29 Alexander Zolotoy Oral administration of r-albuterol against obesity
US7524064B2 (en) * 2004-03-09 2009-04-28 Research Foundation Of The State University Of New York Apparatus and method for assessing retinal damage
US20060074057A1 (en) * 2004-10-04 2006-04-06 Eric Marchewitz Use of chenodeoxycholic acid for reducing adipose tissue
US20060134230A1 (en) * 2004-12-17 2006-06-22 Sal Abraham Weight loss composition and formulation
US20060204599A1 (en) * 2005-03-14 2006-09-14 Wheat Jared R Dietary supplement and method of using same
US20090214682A1 (en) * 2008-02-22 2009-08-27 Heuer Marvin A Composition and methods for weight loss in a subject
US9044606B2 (en) 2010-01-22 2015-06-02 Ethicon Endo-Surgery, Inc. Methods and devices for activating brown adipose tissue using electrical energy
WO2012092056A1 (en) * 2010-12-29 2012-07-05 Ethicon Endo-Surgery, Inc. Methods and devices for activating brown adipose tissue with targeted substance delivery
WO2014056029A1 (en) * 2012-10-08 2014-04-17 Rivalea (Australia) Pty Ltd Animal feed supplement comprising ractopamine and caffeine
US9877434B2 (en) 2013-05-30 2018-01-30 Ecologel Solutions, Llc Granular compositions and methods for drought mitigation
BR112016022039A2 (pt) * 2014-03-26 2017-08-15 Rivalea Australia Pty Ltd Método para aprimorar eficácia de alimentação em ruminantes
US10080884B2 (en) 2014-12-29 2018-09-25 Ethicon Llc Methods and devices for activating brown adipose tissue using electrical energy
US10092738B2 (en) 2014-12-29 2018-10-09 Ethicon Llc Methods and devices for inhibiting nerves when activating brown adipose tissue
WO2016130981A1 (en) 2015-02-13 2016-08-18 Mars, Incorporated Pet food feeding system
US20180055848A1 (en) * 2015-04-14 2018-03-01 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Combination of Albuterol and Caffeine as Synergistic Treatment for Obesity or Sarcopenia
GB201522296D0 (en) 2015-12-17 2016-02-03 Mars Inc Food product to reduce body fat
MX2021013888A (es) 2019-05-16 2022-01-24 Nexus Pharmaceuticals Inc Composiciones que comprenden efedrina o una sal de efedrina y metodos de fabricacion y uso de las mismas.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2390164A1 (fr) * 1977-05-13 1978-12-08 Blanie Paul Association a action anti-asthmatique
FI772858A (fi) 1977-06-03 1978-12-04 Pharmaceutical Export Promotio Avmagningsmedel och foerfarande foer framstaellning daerav
US4364922A (en) * 1980-10-14 1982-12-21 University Of Virginia Alumni Patents Foundation Adenosine antagonists in the treatment and diagnosis of A-V node conduction disturbances
US4525359A (en) * 1982-12-10 1985-06-25 Greenway Frank L Iii Treatment for selective weight control
US5011843A (en) * 1988-05-31 1991-04-30 Iolab Corporation Treatment of glaucoma using phosphodiesterase inhibitors

Also Published As

Publication number Publication date
ES2055911T3 (es) 1994-09-01
RU2109511C1 (ru) 1998-04-27
NO920051L (no) 1992-01-31
CA2063598A1 (en) 1991-01-08
KR0159045B1 (ko) 1998-12-01
JPH04507091A (ja) 1992-12-10
UA27779C2 (uk) 2000-10-16
FI920026A0 (fi) 1992-01-03
DK0480934T3 (da) 1994-11-07
HUT62798A (en) 1993-06-28
LT3536B (en) 1995-11-27
DK339289D0 (da) 1989-07-07
EP0480934B1 (en) 1994-06-29
WO1991000730A1 (en) 1991-01-24
NO920051D0 (no) 1992-01-03
HU220071B (hu) 2001-10-28
DE69010336T2 (de) 1994-11-03
AU638992B2 (en) 1993-07-15
HU9200051D0 (en) 1992-06-29
DE69010336D1 (de) 1994-08-04
HK1001821A1 (en) 1998-07-10
ATE107858T1 (de) 1994-07-15
LV10192B (en) 1995-06-20
EP0480934A1 (en) 1992-04-22
CA2063598C (en) 1997-12-09
US5422352A (en) 1995-06-06
AU5630890A (en) 1991-02-06
JP2584899B2 (ja) 1997-02-26
LTIP702A (en) 1995-01-31

Similar Documents

Publication Publication Date Title
LV10192A (lv) Farmaceitisks pretaptaukosanas sastavs
PT977564E (pt) Forscolina para promocao da massa corporal magra
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
YU47543B (sh) Postupak za dobijanje farmaceutskog preparata za stimulaciju granulocita
BG60102B2 (bg) Метод за получаване на 5-флуор-2(((4-циклопропил- метокси-2-пиридинил)метил)тионил)-1н-бензимидазол
DE69738000D1 (de) Neue Arzneiformulierung enthaltend Budesonide
DE68910159D1 (de) Dosierform für Verabreichung in der Humanmedizin.
ES2116986T3 (es) Composiciones de metal-peptidos y metodos cosmeticos para estimular el crecimiento del cabello.
SE9301290D0 (sv) Anvaendning av en somatostatinanalog
BE898749A (fr) Nouveau procede de preparation de formes galeniques utiles notamment en therapeutique, dietetique, cosmetique et diagnostic
DE3650358D1 (de) Diphosphonate enthaltende pharmazeutische Zusammensetzungen zur Behandlung von Arthrosis.
EP0214254A1 (en) MELATONIN COMPOSITIONS AND USES THEREOF.
ES2176495T3 (es) Utilizacion de un antagonista de la bradiquinina, destinada a inducir y/o estimular el crecimiento de los cabellos y/o frenar su caida.
KR900007434A (ko) 시스타틴을 유효 성분으로하는 치료제
BR9911237A (pt) Novo uso de um derivado de piridazinona
IT8026233A0 (it) Derivato della n-acetil-cisteina ad attivita' terapeutica, procedimento per la sua preparazione e relative composizioni farmaceutiche.
IT8423896A0 (it) Diacilderivati della glicerilfosforilcolina ad attivita' terapeutica, procedimento per laloro preparazione e relative composizioni farmaceutiche.
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
GB2004183A (en) Compositions containing caffeine and ephedrine or their derivatives
AR008155A1 (es) Uso de un compuesto de formula i para preparar un medicamento util para tratar y prevenir la enfermedad cardiovascular post menopausica en mujeres.
KR900017599A (ko) 종양 치료용 약학 조성물
ATE72397T1 (de) Pharmazeutische zusammensetzungen zur behandlung von hyperproliferativer hautkrankheit.
IE780730L (en) Veterinary composition
RU94002713A (ru) Способ лечения детей с синдромом удлиненного интервала qт (романо-уорда)
RU96122371A (ru) Способ лечения эндогенных и послеоперационных увеитов